论文部分内容阅读
目的研究和评价培美曲赛联合顺铂治疗非鳞癌的晚期复发进展非小细胞肺癌的临床疗效及毒副反应。方法选取2010年12月至2012年12月30例组织病理学检查为非鳞癌的晚期复发进展非小细胞肺癌患者行二线化疗:培美曲赛500 mg/m2加入生理盐水100 ml静脉滴注10 min,第1天;顺铂75 mg/m2,分3～5 d。每21天为一个周期,评价疗效及毒副反应。结果总有效率26.7%,疾病控制率70.0%。毒副反应主要为Ⅰ～Ⅱ度骨髓抑制及胃肠道反应。结论培美曲赛联合顺铂二线治疗非鳞癌的晚期非小细胞肺癌显示出良好的有效性及耐受性。
Objective To study and evaluate the clinical efficacy and side effects of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer with advanced non-small cell lung cancer. Methods From December 2010 to December 2012, 30 patients with advanced non-squamous cell carcinoma who underwent histopathological examination undergoing second-line chemotherapy were treated with second-line chemotherapy: Pemetrexed 500 mg / m2 with saline 100 ml intravenously 10 min, day 1; cisplatin 75 mg / m2, divided into 3 ~ 5 d. Every 21 days for a cycle, evaluation of efficacy and toxicity. The total effective rate was 26.7% and the disease control rate was 70.0%. Toxicity mainly Ⅰ ~ Ⅱ degree myelosuppression and gastrointestinal reactions. Conclusion Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer of non-squamous cell carcinoma showed good efficacy and tolerability.